• 933 Citations
  • 10 h-Index
19962012
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where William Hyman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles
docetaxel Medicine & Life Sciences
Cyclophosphamide Medicine & Life Sciences
Prochlorperazine Medicine & Life Sciences
Pentostatin Medicine & Life Sciences
Doxorubicin Medicine & Life Sciences
Ondansetron Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences

Research Output 1996 2012

  • 933 Citations
  • 10 h-Index
  • 11 Article
39 Citations (Scopus)

A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia

Reynolds, C., Di Bella, N., Lyons, R. M., Hyman, W., Richards, D. A., Robbins, G. J., Vellek, M., Boehm, K. A., Zhan, F. & Asmar, L., Jun 1 2012, In : Investigational New Drugs. 30, 3, p. 1232-1240 9 p.

Research output: Contribution to journalArticle

Pentostatin
B-Cell Chronic Lymphocytic Leukemia
Cyclophosphamide
Polymerase Chain Reaction
Infection
10 Citations (Scopus)

Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer

Richards, D. A., Loesch, D., Vukelja, S. J., Wu, H., Hyman, W. J., Nieves, J., Wang, Y., Hu, S., Shonukan, O. O. & Tai, D. F., Oct 1 2011, In : Investigational New Drugs. 29, 5, p. 963-970 8 p.

Research output: Contribution to journalArticle

Pemetrexed
Fallopian Tube Neoplasms
Breast
Maximum Tolerated Dose
liposomal doxorubicin
384 Citations (Scopus)

Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735

Jones, S., Holmes, F. A., O'Shaughnessy, J., Blum, J. L., Vukelja, S. J., Mclntyre, K. J., Pippen, J. E., Bordelon, J. H., Kirby, R. L., Sandbach, J., Hyman, W. J., Richards, D. A., Mennel, R. G., Boehm, K. A., Meyer, W. G., Asmar, L., Mackey, D., Riedel, S., Muss, H. & Savin, M. A., Mar 10 2009, In : Journal of Clinical Oncology. 27, 8, p. 1177-1183 7 p.

Research output: Contribution to journalArticle

docetaxel
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Survival
12 Citations (Scopus)

Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer

Cartwright, T., Kuefler, P., Cohn, A., Hyman, W., Berger, M., Richards, D., Vukelja, S., Nugent, J. E., Ruxer, R. L., Boehm, K. A. & Asmar, L., Nov 2008, In : Clinical Colorectal Cancer. 7, 6, p. 390-397 8 p.

Research output: Contribution to journalArticle

irinotecan
Colorectal Neoplasms
Adenocarcinoma
Therapeutics
Drug Therapy
388 Citations (Scopus)

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

Jones, S. E., Savin, M. A., Holmes, F. A., O'Shaughnessy, J. A., Blum, J. L., Vukelja, S., McIntyre, K. J., Pippen, J. E., Bordelon, J. H., Kirby, R., Sandbach, J., Hyman, W. J., Khandelwal, P., Negron, A. G., Richards, D. A., Anthony, S. P., Mennel, R. G., Boehm, K. A., Meyer, W. G. & Asmar, L., Dec 1 2006, In : Journal of Clinical Oncology. 24, 34, p. 5381-5387 7 p.

Research output: Contribution to journalArticle

docetaxel
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Disease-Free Survival